FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

JUBILANT

872.05
+77.05 (9.69%)
Updated 03:01 03/08 IST

JUBILANT Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for JUBILANT
Disclaimer
0% Bullish
0% Bearish

JUBILANT Buy or Sell - Brokerage Reports

No. of reports in last year
4
No. of analysts
2
Average Consensus Forecast
626.25
Consensus Potential
-36.82%
See JUBILANT Share Price Targets >>

JUBILANT Ratings

Long term JUBILANT rating by FrontPage users
4.3/5 (4 Ratings)
Find answers to all your questions on live JUBILANT message board: Is JUBILANT buy or sell? Should I buy JUBILANT shares? Why are JUBILANT shares falling? Should I invest in JUBILANT stock?

  1. Home
  2. JUBILANT Forum

JUBILANT Share Price Discussion

N
Reputation: 4,593 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
M
Reputation: 86,845 • Jul 31 5:56 AM

Type
Buy
Instrument
JUBILANT
Entry Price
₹815
Price@Trade
₹803.15
Target Price
₹900
Stop Price
₹795
Valid Till
Jul 31, 2020 3:20 AM
Margin
₹81,500 approx for 100 Qty
Status
Exited before entry
Like
Reply (1)
Latest replies
Mayur @mayurgoyal
Jul 31 8:08 AM

Update
Exited before entry
Price @ Update
₹791
C
Reputation: -9 • Jul 30 7:19 AM

Type
Buy
Instrument
JUBILANT
Entry Price
₹787
Price@Trade
₹787
Target Price
₹793
Stop Price
₹784.5
Valid Till
Jul 30, 2020 3:20 AM
Margin
₹78,700 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹784.5
Net P&L
-₹250 (-0.32%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jul 30 7:24 AM

Update
Stoploss Hit
Exit Price
₹784.5
N
Reputation: 4,593 • Jul 30 2:28 AM
Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focus
Indian market witnessed profit-taking at higher levels on Wednesday and the trend is likely to remain volatile on Thursday as well ahead of June F&O expiry.
Moneycontrol
Like
Reply

JUBILANT - chart - 1088729
Buy JUBILANT@770 Tg. 810/1490 CB SL 650
Like
Reply
N
Reputation: 4,593 • Jul 29 3:08 AM
Dr Reddy's expects to launch Remdesivir in August
On another antivral Favipiravir, which is prescribed for mild COVID-19 cases, Dr Reddy's said it will be going ahead with the product, despite Glenmark's clinical trial data hasn't been statistically significant.
Moneycontrol
Like
Reply
N
Reputation: 4,593 • Jul 27 3:53 AM
Correction likely in Nifty but a sustainable move above 11,300 can put bulls in charge
Safe-haven demand and crude prices led to an increase in prices of gold. Investors need to wait for a correction (or a dip) to invest in the precious metal.
Moneycontrol
Like
Reply
N
Reputation: 4,593 • Jul 21 5:38 AM
Jubilant Life hits 52-week high on DCGI nod for Remdesivir; Rakesh Jhunjhunwala raises stake in June quarter
The company's subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug Remdesivir 100 mg/vial (lyophilized injection).
Moneycontrol
Like
Reply
N
Reputation: 4,593 • Jul 21 5:36 AM
This pharma stock rallies 4% as firm gets DCGI nod for Covid drug, RJ ups stake
The company will distribute the drug in the Indian market through its network and it will be available by the first week of August 2020, the filing said.
The Economic Times
Like
Reply

Type
Sell
Instrument
JUBILANT
Entry Price
₹733.95
Price@Trade
₹733.95
Target Price
₹681.5
Stop Price
₹752.3
Valid Till
Jul 21, 2020 3:20 AM
Margin
₹100,551.15 approx for 137 Qty
Status
Validity Over
Exit Price
₹726.95
Net P&L
+₹959 (+0.95%)
Like
Reply (1)
Latest replies
TrackerBot @trackerbot
Jul 21 8:50 AM

Update
Validity Over
Exit Price
₹726.95
Net P&L
+₹959 (+0.95%)
P
Reputation: 159 • Jul 21 3:15 AM

Jubilant Life Sciences is currently trading at Rs. 744.80, up by 23.30 points or 3.23% from its previous closing of Rs. 721.50 on the BSE.

The scrip opened at Rs. 749.00 and has touched a high and low of Rs. 749.55 and Rs. 741.25 respectively.

The BSE group 'A' stock of face va...
Read more...
Like
Reply
N
Reputation: 4,593 • Jul 21 1:23 AM
Jubilant Life Sciences gets DCGI nod for generic version of COVID-19 drug
The company's subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug remdesivir 100 mg/vial (lyophilized injection), Jubilant Life Sciences said in a late night filing to BSE.
Moneycontrol
Like
Reply
N
Reputation: 4,593 • Jul 17 7:43 AM
Exclusive | Zydus Cadila expects to launch Remdesivir in August: Chairman Pankaj Patel
Chairman Pankaj Patel said Zydus Cadila has potential to produce as high as 3-4 lakh doses a month.
Moneycontrol
Like
Reply
B
Reputation: 10,815 • Jul 17 3:22 AM

Type
Buy
Instrument
JUBILANT
Entry Price
₹680
Price@Trade
₹681.15
Target Price
₹690
Stop Price
₹673  ₹675
Valid Till
Jul 17, 2020 3:20 AM
Margin
₹680,000 approx for 1000 Qty
Status
Exited
Exit Price
₹684.2
Net P&L
+₹4,200 (+0.62%)
Like
Reply (3)
Latest replies
TrackerBot @trackerbot
Jul 17 3:24 AM

Update
Trade Entered
Entry Price
₹680
BUMA @mikinkumar
Jul 17 4:20 AM

Update
Stoploss Trailed
Price @ Update
₹682
Original SL
₹673
New SL
₹675
BUMA @mikinkumar
Jul 17 4:27 AM

Update
Exited
Exit Price
₹684.2
Net P&L
+₹4,200 (+0.62%)
N
Reputation: 4,593 • Jul 6 10:43 AM
Exclusive: COVID-19 drug Remdesivir in short supply, prices go up by 6x in black market
While Cipla's drug is yet to be available in the market, Hetero's initial supply of 20,000 vials is nearly exhausted.
Moneycontrol
Like
Reply

Five Pharma stocks with Multi-Bagger Potential..😁
1. Laurus Labs
2. Caplin point
3. Jubliant Life
4. SMS pharma
5. Syngene Int
Buy all dips, Don't chase.
Disclosure: I have already invested in 2 stocks..😁
3
Reply (24)
Latest replies

Then maybe you would have to keep waiting
karun @karun229
Jul 4 9:40 AM

Though I am.mba with core finance in reality the things we have studied have different aspects than the realty

🙏
karun @karun229
Jul 4 9:44 AM

Syngene I will buy at 230
karun @karun229
Jul 4 9:45 AM

Jublient industry can be bought at current levels and dip for upward tragt of 200
H
Reputation: -1,057 • Jul 4 5:29 AM

JUBILANT - chart - 984628
#JUBILANT looking good to breakout
Will make new Life Time High
Stop Loss 640
Target 750-900
Keep holding & trail your Stop loss (it's a good portion stock)
1
Reply
H
Reputation: -1,057 • Jul 3 8:51 AM

Type
Buy
Instrument
JUBILANT
Entry Price
₹684.25
Price@Trade
₹686
Target Price
₹800
Stop Price
₹600
Valid Till
Jul 2, 2021 3:20 AM
Margin
₹171,062.5 approx for 250 Qty
Status
Exited
Exit Price
₹715.35
Net P&L
+₹7,775 (+4.55%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 3 8:52 AM

Update
Trade Entered
Entry Price
₹684.25
Hemant Garg @hemantgarg1989
Jul 8 7:23 AM

Update
Exited
Exit Price
₹715.35
Net P&L
+₹7,775 (+4.55%)

Type
Sell
Instrument
JUBILANT
Entry Price
₹674
Price@Trade
₹671.9
Target Price
₹660
Stop Price
₹682
Valid Till
Jul 3, 2020 3:20 AM
Margin
₹67,400 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹682
Net P&L
-₹800 (-1.19%)
Like
Reply (2)
Latest replies
TrackerBot @trackerbot
Jul 3 3:43 AM

Update
Trade Entered
Entry Price
₹674
TrackerBot @trackerbot
Jul 3 5:09 AM

Update
Stoploss Hit
Exit Price
₹682
N
Reputation: 4,593 • Jun 23 10:36 AM
Dassault Systèmes demonstrates innovations for the life sciences industry in India
The event focused on transforming and digitalizing the life sciences industry in India, which is undergoing core shifts in business processes and manufacturing operations to make it more agile and adaptable.
The Economic Times
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • JUBILANT - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization10,580.71
    Enterprise Value12,147.97
    Price to Earnings50.87
    Price to Book Value4.52
    Return on Capital Employed0.14
    Return on Equity0.12
    Face Value1
    Dividend YieldNA
  • JUBILANT - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    1-Feb-20Nirmal BangBuy792
    31-Jan-20Prabhudas LilladherReduce488
    29-Oct-19Nirmal BangBuy792
    25-Oct-19Prabhudas LilladherReduce433
    29-Jul-19Nirmal BangBuy785
    JUBILANT Brokerage Price Target
  • JUBILANT Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 31780.75814.5766795
    Jul 30780797.7760.15779.9
    Jul 29735.9783.85729.55771.4
    Jul 28735.7741.95732.7735
    Jul 27752.6756733736.8
  • JUBILANT Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹719.31
    30 Day Moving Average₹699.44
    50 Day Moving Average₹636.1
    100 Day Moving Average₹500.83
    200 Day Moving Average₹518.01
  • JUBILANT - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue3,3062,491.220.33
    Operating Profit5393180.69
    Profit Before Tax368114.522.21
    Net Income26379.192.32
  • JUBILANT - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,3402,2490.04
    Total Liabilities2,5232,605-0.03
    Total Assets4,8644,8540
  • JUBILANT - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity558419.150.33
    Cash from Investing Activity-127-43.071.95
    Cash from Financing Activity-470-338.40.39
    Net Cash Flow-4037.69-2.06
  • JUBILANT - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.050.02
    Return on Equity0.120.04
    Return on Capital Employed0.140.08
  • JUBILANT - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.04
    3 Year CAGR Growth in Operating Profit128.73
    3 Year CAGR Growth in EBIDTANA
    3 Year CAGR Growth in Net Income0.28
    3 Yr CAGR Growth - Diluted EPS0.28
  • JUBILANT - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.05
    5 Year CAGR Growth in Operating Profit0.47
    5 Year CAGR Growth in EBIDTA0.46
    5 Year CAGR Growth in Net Income7.07
    3 Yr CAGR Growth - Diluted EPS7.07
  • JUBILANT - Recent News

    keyboard_arrow_down
    NewsBot
    Jul 21 5:38 AM
    Jubilant Life hits 52-week high on DCGI nod for Remdesivir; Rakesh Jhunjhunwala raises stake in June quarter
    Moneycontrol
    NewsBot
    Jul 21 5:36 AM
    This pharma stock rallies 4% as firm gets DCGI nod for Covid drug, RJ ups stake
    The Economic Times
    NewsBot
    Jul 21 1:23 AM
    Jubilant Life Sciences gets DCGI nod for generic version of COVID-19 drug
    Moneycontrol
    NewsBot
    Jun 23 10:36 AM
    Dassault Systèmes demonstrates innovations for the life sciences industry in India
    The Economic Times
    NewsBot
    Jun 16 6:23 AM
    Jubilant Life share at 52-week high as Rakesh Jhunjhunwala raises stake
    Moneycontrol
    NewsBot
    Jun 15 1:51 AM
    Buy Jubilant Life Sciences, target price Rs 867: Anand Rathi
    The Economic Times
    NewsBot
    Jun 14 9:28 AM
    Buy Jubilant Life Sciences; target of Rs 867: Anand Rathi
    Moneycontrol
    NewsBot
    Jun 2 5:08 AM
    Hold Jubilant Life Sciences; target of Rs 414: Prabhudas Lilladher
    Moneycontrol
    NewsBot
    Jun 2 2:23 AM
    Buy Jubilant Life Sciences; target of Rs 550: ICICI Direct
    Moneycontrol
    NewsBot
    Jun 1 8:58 AM
    Buy Jubilant Life Sciences; target of Rs 515: Motilal Oswal
    Moneycontrol
  • JUBILANT - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020